Bayer to Advance Two First-of-Its-Kind Investigational Cell and Gene Therapies for Parkinson’s Disease

Bayer AG announced that BlueRock Therapeutics successfully administered the first dose of its investigational pluripotent stem cell-derived dopaminergic neurons, named DA01, to a Parkinson’s disease patient in their open-label Phase I clinical safety and tolerability study.